- €1.45bn
 - €2.06bn
 - €726.20m
 
Annual balance sheet for Biotest AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st  | 2021 December 31st  | 2022 December 31st  | 2023 December 31st  | 2024 December 31st  | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | ARS | ARS | ARS | ARS | ARS | 
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 90.6 | 118 | 144 | 108 | 108 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 167 | 151 | 164 | 205 | 201 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 556 | 522 | 619 | 757 | 810 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 548 | 550 | 548 | 578 | 571 | 
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,131 | 1,104 | 1,203 | 1,411 | 1,434 | 
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 106 | 106 | 130 | 385 | 160 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 690 | 724 | 832 | 912 | 903 | 
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 442 | 380 | 371 | 499 | 531 | 
| Total Liabilities & Shareholders' Equity | 1,131 | 1,104 | 1,203 | 1,411 | 1,434 | 
| Total Common Shares Outstanding |